Ngā hua rapu - Lisa M. Almond
- E whakaatu ana i te 1 - 11 hua o te 11
-
1
-
2
Physiologically‐Based Pharmacokinetic‐Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor‐Tezacaftor‐Ivacaftor With Nirmatrelvir‐Ritonavir for the Treatment of COVID‐... mā Eunjin Hong, Lisa M. Almond, Peter S. Chung, Adupa P. Rao, Paul M. Beringer
I whakaputaina 2022Artigo -
3
The Effects of Protease Inhibitors and Nonnucleoside Reverse Transcriptase Inhibitors on P-Glycoprotein Expression in Peripheral Blood Mononuclear Cells In Vitro mā Becky Chandler, Lisa M. Almond, Jennifer Lynn Ford, Andrew Owen, Patrick G. Hoggard, Saye Khoo, David Back
I whakaputaina 2003Artigo -
4
-
5
Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an In Vitro–In Vivo Extrapolation Model mā Marco Siccardi, Lisa M. Almond, Alessandro Schipani, Chantal Csajka, Catia Marzolini, Christoph Wyen, Norbert H. Brockmeyer, Marta Boffito, Andrew Owen, David Back
I whakaputaina 2012Artigo -
6
Incorporating Population Variability and Susceptible Subpopulations into Dosimetry for High-Throughput Toxicity Testing mā Barbara A. Wetmore, Brittany Allen, Harvey J. Clewell, Timothy A. Parker, John F. Wambaugh, Lisa M. Almond, Mark A. Sochaski, Russell S. Thomas
I whakaputaina 2014Artigo -
7
Development of a Multicompartment Permeability‐Limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis Drugs mā Lu Gaohua, J. R. Wedagedera, Ben G. Small, Lisa M. Almond, Klaus Romero, Dirk M. Hermann, Debra Hanna, Masoud Jamei, I. Gardner
I whakaputaina 2015Artigo -
8
Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug–drug interactions mā Howard Burt, Sibylle Neuhoff, Lisa M. Almond, Lu Gaohua, Matthew D. Harwood, Masoud Jamei, Amin Rostami‐Hodjegan, Geoffrey T. Tucker, K Rowland‐Yeo
I whakaputaina 2016Artigo -
9
Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model mā Lisa M. Almond, Sophie Mukadam, I. Gardner, K. Okialda, Susan Wong, Oliver Hatley, Sun Tee Tay, K Rowland‐Yeo, Masoud Jamei, Amin Rostami‐Hodjegan, Jane R. Kenny
I whakaputaina 2016Artigo -
10
Safety of elexacaftor/tezacaftor/ivacaftor dose reduction: Mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series mā Eunjin Hong, Regina Li, Alan Shi, Lisa M. Almond, Joshua Wang, Amin Z. Khudari, Soumar Haddad, Sarkis Sislyan, Marissa Angelich, Peter S. Chung, Adupa P. Rao, Paul M. Beringer
I whakaputaina 2023Artigo -
11
An in vitro toolbox to accelerate anti-malarial drug discovery and development mā Susan A. Charman, Alice Andreu, Helena Barker, Scott Blundell, Anna Campbell, Michael G. Campbell, Gong� Chen, Francis C. K. Chiu, Elly Crighton, Kasiram Katneni, Julia Morizzi, Rahul Patil, Thao Pham, Eileen Ryan, Jessica Saunders, David M. Shackleford, Karen L. White, Lisa M. Almond, Maurice Dickins, Dennis A. Smith, Joerg J. Moehrle, Jeremy N. Burrows, Nada Abla
I whakaputaina 2020Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Pharmacology
Medicine
Pharmacokinetics
Biochemistry
Biology
Chemistry
Physiologically based pharmacokinetic modelling
In vitro
Internal medicine
Antiretroviral therapy
Enzyme
In vivo
Viral load
Cytochrome P450
Efavirenz
Gene
Human immunodeficiency virus (HIV)
Immunology
Antibiotics
Biotechnology
CYP3A
CYP3A4
Cystic fibrosis
Cystic fibrosis transmembrane conductance regulator
Drug
Drug interaction
Environmental health
Genetics
Ivacaftor
Lung